ANALYSIS OF TR3 RECEPTOR IN APOPTOSIS OF PROSTATE CANCER AND APPLICATION FOR DIAGNOSIS OF PROSTATE CANCER RECCURENCE
ANALYSIS OF TR3 RECEPTOR IN APOPTOSIS OF PROSTATE CANCER AND APPLICATION FOR DIAGNOSIS OF PROSTATE CANCER RECCURENCE
批准号:
08671830
负责人:
UEMURA Hiroji
金额:
$1.41万
依托单位:
依托单位国家:
日本
项目类别:
Grant-in-Aid for Scientific Research (C)
财政年份:
1996
资助国家:
日本
项目状态:
已结题
起止时间:
1996 至 1998
中文摘要
点击翻译按钮获取中文摘要
英文摘要
(1) A role of TR3 orphan receptor in drug-induced prostate apoptosisIn androgen-responsive LNCaP human prostatic cancer cells, human TR3 orphan receptor can be rapidly induced by stimulation of androgen or growth factors (i.e., EGF or FGF). In contrast, ablation of androgen by castration can also induce the expression of TR3 orphan receptor gene in rat ventral prostate which underwent programmed cell death (apoptosis) characterized by DNA fragmentation ladder. This phenomenon prompted us to further analyze the roles of human TR3 orphan receptor in apoptosis-induced prostate cancer cells. Northern blot analysis shows that human TR3 orphan receptor can be induced rapidly after treatment of 10 mM calcium ionophore or 300 mM etoposide (VP 16) in LNCaP cells. Antisense TR3 orphan receptor stable transfectant LNCaP cells indicated a much higher concentration of etoposide was needed to show the similar apoptosis as compared to the control (vector) stable transfectant LNCaP cells. Together, ou … More r data suggest that human TR3 orphan receptor may play an important role of drug-induced apoptosis in human prostate cancer cells.(2) Induction of an intronic enhancer of the human ciliary neurotrophic factor receptor (CNTFR) gene by the TR3 orphan receptorA hormone response element, CNTER-NERB (5'-AAAGGTCA-3') has been identified in the fifth intron of the alpha component of CNTFR gene for the human TR3 orphan receptor. A specific binding between in vitro expressed TR3 and CNTFR-NBRE was demonstrated by using electrophoretic mobility shift assay. A reporter gene assay using CAT showed that CNTFR has an enhancer activity that could be induced by TR3 receptor in a dose-dependent manner. This induction was significantly reduced in the absence of CNTFR-BNBRE. Together, these results indicate CNTFR-NBRE is sufficient to mediate TR3 action in inducing the enhancer activity of CNTFR. Our finding may, therefore, suggest CNTFR is a target gene regulated by TR3 and expand the role of TR3 in the nervous system.(3) In situ hybridization of TR3 receptor in prostate cancer tissues.Recently, Jenkins et al. showed clear data in which c-myc amplification in prostate cancer tissues and metastatic lymphnodes was detected using fluorescence in situ hybridization. Our in situ hybridization data in human prostate cancer, benign prostate hypertrophy, and normal prostate tissues revealed that the expression patterns of TR3 orphan receptor mRNA were very similar to those of c-myc. More interestingly, TR3 orphan receptor mRNAs were more highly expressed in prostate cancer area than in adjacent normal or benign hypertrophic tissue. Furthermore, these expressions were highly seen in poorly differentiated adenocarcinoma area. These data suggest that the TR3 orphan receptor may play some important roles in development or progression of prostate cancer in the same manner as the c-myc oncogene.(4) Telomerase activities in prostate cancer tissues.We analyzed the telomerase activity in association with the pathological differentiation of prostate cancer. Telomerase activity was examined by PCR-based telomeric repeat amplification protocol (TRAP) assay. The results showed that most of prostate cancer tissues (90%) displayed telomerase activity and high activity in primary and biopsy specimens were more frequent detected in poorly differentiated adenocarcinoma. Also, the expression of catalytic subunit, hTERT, was detected by RT-PCR. It revealed that the expression in 70% of prostate cancer tissues was more highly seen in comparison with those in normal prostate tissues. Less
期刊论文(19)
专著(0)
科研奖励(0)
会议论文
登录
查看更多内容
Y.Lin, H.Uemura et al.: "Telomerase activity in primary prostate cancer"J.of Urology. 157. 1161-1165 (1997)
Y.Lin、H.Uemura 等人:“原发性前列腺癌中的端粒酶活性”J.of Urology。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
X. Mu, W.J.Young, Y. Lin, H. Uemura and C. Chang: "Induction of an intronic enhancer of the human ciliary neurotrophic factor receptor gene by the TR3 orphan receptor"Endocrine. 9,1. 27-32 (1998)
X. Mu、W.J.Young、Y. Lin、H. Uemura 和 C. Chang:“TR3 孤儿受体诱导人睫状神经营养因子受体基因的内含子增强子”内分泌。
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
上村博司: "Key Word 1997-98 泌尿器系" (斎藤泰,小林知彦,穂坂正彦編)先端医学社, 227 (1996)
Hiroshi Uemura:“Key Word 1997-98 Urinary System”(由 Yasushi Saito、Tomohiko Kobayashi 和 Masahiko Hosaka 编辑)Sendai Igakusha,227 (1996)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
X,Mu.H.Uemura et al: "Induction of an intronic enhanced of the CNTFRα gene by the TR3 orphan receptor" Endocrine. 9. 27-32 (1998)
X,Mu.H.Uemura 等人:“TR3 孤儿受体诱导内含子增强的 CNTFRα 基因”内分泌。 9. 27-32 (1998)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
H.Miyamoto et al.: "Molecular Basis of Sex Hormore Receptov Function" H.Gromeneyer,U.Farhmann and K.Parczyk, 236 (1998)
H.Miyamoto 等人:“性激素受体功能的分子基础”H.Gromeneyer、U.Farhmann 和 K.Parczyk,236 (1998)
DOI:
--
发表时间:
期刊:
影响因子:
--
作者:
[]
通讯作者:
共 19 条
Analysis of the regulation of androgen receptor by renin-angiotensin system in prostate cancer
-
批准号:22591774
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.91万
-
财政年份:2010
-
负责人:UEMURA Hiroji
-
依托单位:
Analysis of the effect by angiotensin II-induced oxidative stress in the development of prostate cancer
-
批准号:19591865
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$3.0万
-
财政年份:2007
-
负责人:UEMURA Hiroji
-
依托单位:
Analysis of bioactive function of angiotensin II in prostate cancer
-
批准号:17591689
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.18万
-
财政年份:2005
-
负责人:UEMURA Hiroji
-
依托单位:
Molecular mechanism of chemoprevention against prostate cancer by phytosterol
-
批准号:14571510
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.24万
-
财政年份:2002
-
负责人:UEMURA Hiroji
-
依托单位:
Functional Analysis of Steroid hormone orphan receptor in hormone refractory prostate cancer
-
批准号:11671568
-
项目类别:Grant-in-Aid for Scientific Research (C)
-
资助金额:$2.37万
-
财政年份:1999
-
负责人:UEMURA Hiroji
-
依托单位:
海外基金